Eli Lilly and Company beat EPS estimates 78% of the time across 18 reported quarters (14 beats, 4 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $9.01 | — | — | Miss |
| Q1 FY2026 | $7.37 | — | — | Miss |
| Q1 FY2026 | $6.97 | $8.55 | +22.7% | Beat |
| 2026-02-04 | $6.91 | $7.54 | +9.1% | Beat |
| Q3 FY2025 | $5.69 | $7.02 | +23.4% | Beat |
| Q2 FY2025 | $5.60 | $6.31 | +12.7% | Beat |
| Q1 FY2025 | $3.26 | $3.34 | +2.5% | Beat |
| 2025-02-06 | $5.03 | $5.32 | +5.8% | Beat |
| Q3 FY2024 | $1.47 | $1.18 | -19.7% | Miss |
| Q2 FY2024 | $2.60 | $3.92 | +50.8% | Beat |
| Q1 FY2024 | $2.46 | $2.58 | +4.9% | Beat |
| 2024-02-06 | $2.22 | $2.49 | +12.2% | Beat |
Back to LLY overview · LLY holders · LLY KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.